Cancer has become a significant global public health issue， severely impacting public health and societal development. Despite advances in tumor treatment methods in recent years and a gradual decline in cancer mortality rates， drug-related adverse reactions and drug resistance remain substantial challenges. Traditional Chinese medicine （TCM） has demonstrated significant clinical efficacy in cancer treatment and small side effects， making it widely applied in the field of oncology. Xuefu Zhuyutang， derived from Yilin Gaicuo， is known for its abilities to invigorate blood circulation， dispel blood stasis， promote Qi flow， and alleviate pain. It was specifically formulated by the esteemed WANG Qingren of the Qing dynasty for the "blood stasis syndrome in the blood mansion" and is commonly used to treat Qi stagnation and blood stasis syndrome. Clinical studies have shown that Xuefu Zhuyutang， when combined with conventional Western medications， produces significant effects in the treatment of malignant tumors such as liver cancer， lung cancer， and cervical cancer. It substantially reduces the incidence of adverse reactions following Western treatments， including radiation esophagitis， radiation encephalopathy， radiation-induced oral mucositis， and edema. Additionally， it alleviates cancer-related pain and fever， blood hypercoagulability， and associated complications such as depression and anxiety， and also mitigates chemotherapy-induced side effects like hand-foot syndrome. Basic research has demonstrated its potential anti-tumor mechanisms， including the inhibition of Wnt/β-catenin signaling pathway activation， suppression of mitogen-activated protein kinase （MAPK） pathway activation， and anti-tumor angiogenesis. Pharmacological studies have revealed that its active components inhibit tumor cell proliferation and migration， induce tumor cell apoptosis， suppress tumor angiogenesis， enhance the cytotoxicity of natural killer cells against tumors， improve the tumor microenvironment， and regulate immune function. This paper reviewed the latest research progress on Xuefu Zhuyutang in the treatment of malignant tumors from four aspects： theoretical exploration， clinical studies， mechanisms of action， and pharmacological basis， aiming to provide insights and methods for the clinical diagnosis and treatment of malignant tumors.

Cancer has become a significant global public health issue， severely impacting public health and societal development. Despite advances in tumor treatment methods in recent years and a gradual decline in cancer mortality rates， drug-related adverse reactions and drug resistance remain substantial challenges. Traditional Chinese medicine （TCM） has demonstrated significant clinical efficacy in cancer treatment and small side effects， making it widely applied in the field of oncology. Xuefu Zhuyutang， derived from Yilin Gaicuo， is known for its abilities to invigorate blood circulation， dispel blood stasis， promote Qi flow， and alleviate pain. It was specifically formulated by the esteemed WANG Qingren of the Qing dynasty for the "blood stasis syndrome in the blood mansion" and is commonly used to treat Qi stagnation and blood stasis syndrome. Clinical studies have shown that Xuefu Zhuyutang， when combined with conventional Western medications， produces significant effects in the treatment of malignant tumors such as liver cancer， lung cancer， and cervical cancer. It substantially reduces the incidence of adverse reactions following Western treatments， including radiation esophagitis， radiation encephalopathy， radiation-induced oral mucositis， and edema. Additionally， it alleviates cancer-related pain and fever， blood hypercoagulability， and associated complications such as depression and anxiety， and also mitigates chemotherapy-induced side effects like hand-foot syndrome. Basic research has demonstrated its potential anti-tumor mechanisms， including the inhibition of Wnt/β-catenin signaling pathway activation， suppression of mitogen-activated protein kinase （MAPK） pathway activation， and anti-tumor angiogenesis. Pharmacological studies have revealed that its active components inhibit tumor cell proliferation and migration， induce tumor cell apoptosis， suppress tumor angiogenesis， enhance the cytotoxicity of natural killer cells against tumors， improve the tumor microenvironment， and regulate immune function. This paper reviewed the latest research progress on Xuefu Zhuyutang in the treatment of malignant tumors from four aspects： theoretical exploration， clinical studies， mechanisms of action， and pharmacological basis， aiming to provide insights and methods for the clinical diagnosis and treatment of malignant tumors.

Objective To analyze the changes in patients with neovascular age-related macular degeneration(nAMD)before and after treatment with faricimab or ranibizumab.Methods A prospective study was conducted on 20 nAMD patients(20 eyes)who received treatment at the Ophthalmology Department of Wuhu Hospital affiliated with East China Normal University.nAMD was diagnosed with fluorescein fundus angiography,indocyanine green angiography,and optical coherence tomography(OCT).The central macular thickness(CMT),choroidal neovascularization(CNV)cross-sectional area(CSA),and CNV blood flow area(CFA)of the patients at baseline and after 4,12,and 24 weeks of anti-vascular endothelial growth factor(VEGF)treatment.The changes in index at different time periods and the differences in results between the two groups were studied.Results There were no statistically significant differences in age,gender,CNV type,OCT,and optical coherence tomography angiography(OCTA)morphology between the two groups of patients at baseline(all P＞0.05).CMT,CSA,and CFA decreased in both groups after treatment(all P＜0.05).CMT showed a gradual decrease in both groups after 4 and 12 weeks of treatment(all P＜0.05).There was no statistically significant difference in CMT between 12 and 24 weeks after treatment in the faricimab group(P=0.096).In the ranibizumab group,CMT increased 24 weeks after treatment,compared with that 12 weeks after treatment(P=0.004).CSA and CFA de-creased in both groups after 12 weeks of treatment(both P＜0.05).There was no statistically significant difference in CSA and CFA between 12 and 24 weeks after treatment in the faricimab group(P=0.085,0.095).In the ranibizumab group,CSA and CFA increased 24 weeks after treatment,compared with those 12 week after treatment(P=0.001,0.000).Inter-group comparisons showed that the CMT of patients in the faricimab group was lower than that in the ranibizumab group af-ter 24 weeks of treatment(P=0.022).There was no statistically significant difference in CSA and CFA at each time period for both groups(all P＞0.05).Conclusion Faricimab and ranibizumab have similar efficacy in the treatment of nAMD patients,but faricimab is superior to ranibizumab in sustained effects.

[This corrects the article DOI: 10.1016/j.apsb.2019.01.013.].

An analysis of 24 144 norovirus sequences from Asia and Russia deposited in GenBank between 1995 and 2023 was conducted,to understand the temporal and spatial variations in norovirus genotypes in these regions.Norovirus sequences from Asia and Russia were downloaded in FASTA format from GenBank for the years 1995-2023,and analyzed in Excel,R language,and GraphPad Prism for data visualization.The number of norovirus sequences submitted to GenBank increased annually from 2004 and peaked in 2015.Notably,China and Japan contributed 62.3％of all submitted norovirus sequences.These sequences encompassed 31 capsid genotypes(C-type),with GⅠ accounting for 9％and GⅡ accounting for 90％.Additionally,49 polymerase types(P-type)were identified,along with 68 combinations of CP types;among the analyzed recombinant sequences(4 460 entries in total),approxi-mately 41％belonged to three predominant recombinant strains:GⅡ.2[P16],GⅡ.4[P31],and GⅡ.4[P16].This analysis provides valuable insights into the distribution characteristics of norovirus genotypes across Asia and Russia over time,thereby supporting vac-cine design and evaluation efforts.

Objective To analyze the changes in patients with neovascular age-related macular degeneration(nAMD)before and after treatment with faricimab or ranibizumab.Methods A prospective study was conducted on 20 nAMD patients(20 eyes)who received treatment at the Ophthalmology Department of Wuhu Hospital affiliated with East China Normal University.nAMD was diagnosed with fluorescein fundus angiography,indocyanine green angiography,and optical coherence tomography(OCT).The central macular thickness(CMT),choroidal neovascularization(CNV)cross-sectional area(CSA),and CNV blood flow area(CFA)of the patients at baseline and after 4,12,and 24 weeks of anti-vascular endothelial growth factor(VEGF)treatment.The changes in index at different time periods and the differences in results between the two groups were studied.Results There were no statistically significant differences in age,gender,CNV type,OCT,and optical coherence tomography angiography(OCTA)morphology between the two groups of patients at baseline(all P＞0.05).CMT,CSA,and CFA decreased in both groups after treatment(all P＜0.05).CMT showed a gradual decrease in both groups after 4 and 12 weeks of treatment(all P＜0.05).There was no statistically significant difference in CMT between 12 and 24 weeks after treatment in the faricimab group(P=0.096).In the ranibizumab group,CMT increased 24 weeks after treatment,compared with that 12 weeks after treatment(P=0.004).CSA and CFA de-creased in both groups after 12 weeks of treatment(both P＜0.05).There was no statistically significant difference in CSA and CFA between 12 and 24 weeks after treatment in the faricimab group(P=0.085,0.095).In the ranibizumab group,CSA and CFA increased 24 weeks after treatment,compared with those 12 week after treatment(P=0.001,0.000).Inter-group comparisons showed that the CMT of patients in the faricimab group was lower than that in the ranibizumab group af-ter 24 weeks of treatment(P=0.022).There was no statistically significant difference in CSA and CFA at each time period for both groups(all P＞0.05).Conclusion Faricimab and ranibizumab have similar efficacy in the treatment of nAMD patients,but faricimab is superior to ranibizumab in sustained effects.

An analysis of 24 144 norovirus sequences from Asia and Russia deposited in GenBank between 1995 and 2023 was conducted,to understand the temporal and spatial variations in norovirus genotypes in these regions.Norovirus sequences from Asia and Russia were downloaded in FASTA format from GenBank for the years 1995-2023,and analyzed in Excel,R language,and GraphPad Prism for data visualization.The number of norovirus sequences submitted to GenBank increased annually from 2004 and peaked in 2015.Notably,China and Japan contributed 62.3％of all submitted norovirus sequences.These sequences encompassed 31 capsid genotypes(C-type),with GⅠ accounting for 9％and GⅡ accounting for 90％.Additionally,49 polymerase types(P-type)were identified,along with 68 combinations of CP types;among the analyzed recombinant sequences(4 460 entries in total),approxi-mately 41％belonged to three predominant recombinant strains:GⅡ.2[P16],GⅡ.4[P31],and GⅡ.4[P16].This analysis provides valuable insights into the distribution characteristics of norovirus genotypes across Asia and Russia over time,thereby supporting vac-cine design and evaluation efforts.

Objectives:This study aims to explore the clinical significance of lateral pelvic sentinel lymph node biopsy (SLNB) using indocyanine green (ICG) fluorescence navigation in laparoscopic lateral pelvic lymph node dissection (LLND) and evaluate the accuracy and feasibility of this technique to predict the status of lateral pelvic lymph nodes (LPLNs).Methods:The clinical and pathological characteristics, surgical outcomes, lymph node findings and perioperative complications of 16 rectal cancer patients who underwent SLNB using ICG fluorescence navigation in laparoscopic LLND in the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during April 2017 and October 2022 were retrospectively collected and analyzed. The patients did not receive preoperative neoadjuvant radiotherapy and presented with LPLNs but without LPLN enlargement (MRI showed the maximum short axes of the LPLNs were ≥5 mm and <10 mm at first visit).Results:All 16 patients were successfully performed SLNB using ICG fluorescence navigation in laparoscopic LLND. Three patients underwent bilateral LLND and 13 patients underwent unilateral LLND. The lateral pelvic sentinel lymph nodes (SLNs) were clearly fluorescent before dissection in 14 patients and the detection rate of SLNs for these patients was 87.5%. Lateral pelvic SLN metastasis was diagnosed in 2 patients and negative results were found in 12 patients by frozen pathological examinations. Among the 14 patients in whom lateral pelvic SLNs were detected, the dissected lateral pelvic non-SLNs were all negative. All dissected LPLNs were negative in two patients without fluorescent lateral pelvic SLNs. The specificity, sensitivity, negative predictive value, and accuracy was 85.7%, 100%, 100%, and 100%, respectively.Conclusions:This study indicates that lateral pelvic SLNB using ICG fluorescence navigation shows promise as a safe and feasible procedure with good accuracy. This technique may replace preventive LLND for locally advanced lower rectal cancer.